MEDIMABBIO, a Korean biotech specializing in next-generation immunotherapies, has raised approximately USD 18.5 million(KRW 25.6 billion) in its Series B funding round.

The round saw follow-on participation from six existing investors — KB Investment, Smilegate Investment, BNH Investment, Hyundai Investment Partners, iM Investment Partners, and Timefolio Asset Management — as well as the addition of eight new institutional investors, including Yuanta Investment, Seoul Investment Partners, Sneak peek Investment, Union Investment Partners, AION Investment Management, EN Venture Partners, Dongbang FTL, and HLB Biostep.

Founded by co-CEOs Yoohoe Kang and Hongseok Cho, both former researchers at Samsung Advanced Institute of Technology, MEDIMABBIO is an innovative biopharmaceutical company developing autoimmune and immuno-oncology therapeutics based on its proprietary MediLink™ fusion-antibody platform. By engineering antibodies fused with immune-modulating cytokines, the company enables precise control of immune signaling, establishing a differentiated competitive edge. Its lead candidate, MFA031, is a next-generation fusion therapy targeting immune receptors, designed to restore immune equilibrium across a broad range of inflammatory conditions such as autoimmune diseases and transplant rejection.

The newly raised capital will be allocated toward advancing commercialization of MFA031 and other key pipeline assets, expanding the follow-on pipeline, and strengthening global technology partnerships — with the goal of accelerating market entry in autoimmune therapeutics and establishing leadership in the global next-generation immunotherapy arena.

MEDIMABBIO leveraged the networking and R&D infrastructure of Seoul Bio Hub — a biotech innovation platform established by the Seoul Metropolitan Government — to expand its global partnerships and lay the groundwork for this financing.

In August 2024, the company was selected for the South Korean Ministry of SMEs and Startups’ “Scale-Up TIPS” program, affirming the technological excellence and growth potential of its platform. In September, MEDIMABBIO was ranked first at Innovation Tiger 2025, hosted at Shonan iPark, a global bio-innovation cluster in Japan — further validating its scientific and commercial competitiveness on the global stage.

At the upcoming “Cytokine 2025” international conference in Seattle this November, the company will officially present preclinical results of MFA031 for autoimmune indications, expecting renewed recognition of its fusion-antibody–based immune-modulation technology.

CEO Yoohoe Kang stated, “This financing enables us to further strengthen collaborations with global pharmaceutical partners and accelerate the development and commercialization of next-generation immunotherapies.”